VIRAX BIOLABS GROUP LTD (VRAX) Fundamental Analysis & Valuation

NASDAQ:VRAX • KYG9495L1251

Current stock price

0.1596 USD
+0 (+0.44%)
At close:
0.1539 USD
-0.01 (-3.57%)
Pre-Market:

This VRAX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. VRAX Profitability Analysis

1.1 Basic Checks

  • In the past year VRAX has reported negative net income.
  • In the past year VRAX has reported a negative cash flow from operations.
  • VRAX had negative earnings in each of the past 5 years.
  • VRAX had a negative operating cash flow in each of the past 5 years.
VRAX Yearly Net Income VS EBIT VS OCF VS FCFVRAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -2M -4M -6M

1.2 Ratios

  • VRAX has a Return On Assets of -98.75%. This is amonst the worse of the industry: VRAX underperforms 94.00% of its industry peers.
  • VRAX has a worse Return On Equity (-106.24%) than 75.00% of its industry peers.
Industry RankSector Rank
ROA -98.75%
ROE -106.24%
ROIC N/A
ROA(3y)-90.9%
ROA(5y)-1063.54%
ROE(3y)-97.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRAX Yearly ROA, ROE, ROICVRAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

1.3 Margins

  • VRAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRAX Yearly Profit, Operating, Gross MarginsVRAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 -20K -40K -60K -80K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. VRAX Health Analysis

2.1 Basic Checks

  • VRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, VRAX has more shares outstanding
  • The number of shares outstanding for VRAX has been reduced compared to 5 years ago.
  • The debt/assets ratio for VRAX is higher compared to a year ago.
VRAX Yearly Shares OutstandingVRAX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
VRAX Yearly Total Debt VS Total AssetsVRAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

2.2 Solvency

  • An Altman-Z score of 3.45 indicates that VRAX is not in any danger for bankruptcy at the moment.
  • VRAX has a better Altman-Z score (3.45) than 71.00% of its industry peers.
  • VRAX has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
  • VRAX has a Debt to Equity ratio of 0.09. This is in the better half of the industry: VRAX outperforms 76.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 3.45
ROIC/WACCN/A
WACC10.32%
VRAX Yearly LT Debt VS Equity VS FCFVRAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 5M -5M

2.3 Liquidity

  • A Current Ratio of 11.35 indicates that VRAX has no problem at all paying its short term obligations.
  • VRAX has a Current ratio of 11.35. This is amongst the best in the industry. VRAX outperforms 98.00% of its industry peers.
  • VRAX has a Quick Ratio of 11.20. This indicates that VRAX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 11.20, VRAX belongs to the top of the industry, outperforming 98.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.35
Quick Ratio 11.2
VRAX Yearly Current Assets VS Current LiabilitesVRAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. VRAX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 51.89% over the past year.
  • VRAX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -96.47%.
  • VRAX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -42.47% yearly.
EPS 1Y (TTM)51.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.72%
Revenue 1Y (TTM)-96.47%
Revenue growth 3YN/A
Revenue growth 5Y-42.47%
Sales Q2Q%-68%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • The Revenue is expected to grow by 16.04% on average over the next years. This is quite good.
EPS Next Y166.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year66.97%
Revenue Next 2Y-29.64%
Revenue Next 3Y-4.67%
Revenue Next 5Y16.04%

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VRAX Yearly Revenue VS EstimatesVRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5M 10M 15M 20M 25M
VRAX Yearly EPS VS EstimatesVRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 0 -0.05 -0.1 -0.15

More info and screens

Find the best growth stocksShow best growing peers

4

4. VRAX Valuation Analysis

4.1 Price/Earnings Ratio

  • VRAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • The Price/Forward Earnings ratio is 3.91, which indicates a rather cheap valuation of VRAX.
  • Based on the Price/Forward Earnings ratio, VRAX is valued cheaper than 100.00% of the companies in the same industry.
  • VRAX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.29.
Industry RankSector Rank
PE N/A
Fwd PE 3.91
VRAX Price Earnings VS Forward Price EarningsVRAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRAX Per share dataVRAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

  • VRAX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VRAX Dividend Analysis

5.1 Amount

  • VRAX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VRAX Fundamentals: All Metrics, Ratios and Statistics

VIRAX BIOLABS GROUP LTD

NASDAQ:VRAX (4/24/2026, 8:13:34 PM)

Premarket: 0.1539 -0.01 (-3.57%)

0.1596

+0 (+0.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A
Earnings (Next)12-13
Inst Owners9.61%
Inst Owner Change0%
Ins Owners3.82%
Ins Owner Change0%
Market Cap3.18M
Revenue(TTM)3.00K
Net Income(TTM)-5.64M
Analysts82.86
Price Target1.02 (539.1%)
Short Float %0%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-95%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.91
P/S 1059.74
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB 0.6
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)0.04
Fwd EY25.56%
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0
BVpS0.27
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -98.75%
ROE -106.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.9%
ROA(5y)-1063.54%
ROE(3y)-97.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 123.76%
Cap/Sales 16580%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.35
Quick Ratio 11.2
Altman-Z 3.45
F-Score1
WACC10.32%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)4134.9%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.72%
EPS Next Y166.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-96.47%
Revenue growth 3YN/A
Revenue growth 5Y-42.47%
Sales Q2Q%-68%
Revenue Next Year66.97%
Revenue Next 2Y-29.64%
Revenue Next 3Y-4.67%
Revenue Next 5Y16.04%
EBIT growth 1Y6.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year161.03%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.95%
OCF growth 3YN/A
OCF growth 5YN/A

VIRAX BIOLABS GROUP LTD / VRAX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for VIRAX BIOLABS GROUP LTD?

ChartMill assigns a fundamental rating of 3 / 10 to VRAX.


What is the valuation status for VRAX stock?

ChartMill assigns a valuation rating of 4 / 10 to VIRAX BIOLABS GROUP LTD (VRAX). This can be considered as Fairly Valued.


How profitable is VIRAX BIOLABS GROUP LTD (VRAX) stock?

VIRAX BIOLABS GROUP LTD (VRAX) has a profitability rating of 0 / 10.


What is the earnings growth outlook for VIRAX BIOLABS GROUP LTD?

The Earnings per Share (EPS) of VIRAX BIOLABS GROUP LTD (VRAX) is expected to grow by 166.67% in the next year.